Business Description
Dogwood Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US92829J1043
Share Class Description:
DWTX: Ordinary SharesDescription
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.42 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 47.7 | |||||
| 3-Year EPS without NRI Growth Rate | 48.9 | |||||
| 3-Year FCF Growth Rate | 31 | |||||
| 3-Year Book Growth Rate | -62 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 65.83 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.27 | |||||
| 9-Day RSI | 61.82 | |||||
| 14-Day RSI | 53.25 | |||||
| 6-1 Month Momentum % | -61.51 | |||||
| 12-1 Month Momentum % | -82.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | |||||
| Quick Ratio | 1.71 | |||||
| Cash Ratio | 1.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -186.98 | |||||
| ROA % | -154.25 | |||||
| ROIC % | -2344.2 | |||||
| ROC (Joel Greenblatt) % | -2371.89 | |||||
| ROCE % | -190.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.36 | |||||
| Price-to-Tangible-Book | 3.34 | |||||
| EV-to-EBIT | -0.18 | |||||
| EV-to-Forward-EBIT | -0.25 | |||||
| EV-to-EBITDA | -0.18 | |||||
| EV-to-FCF | -0.38 | |||||
| Price-to-Net-Current-Asset-Value | 3.38 | |||||
| Price-to-Net-Cash | 4.48 | |||||
| Earnings Yield (Greenblatt) % | -555.56 | |||||
| FCF Yield % | -113.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DWTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dogwood Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.55 | ||
| Beta | 1.69 | ||
| Volatility % | 76.38 | ||
| 14-Day RSI | 53.25 | ||
| 14-Day ATR ($) | 0.362391 | ||
| 20-Day SMA ($) | 2.500485 | ||
| 12-1 Month Momentum % | -82.91 | ||
| 52-Week Range ($) | 1.62 - 23.5 | ||
| Shares Outstanding (Mil) | 1.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dogwood Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dogwood Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dogwood Therapeutics Inc Frequently Asked Questions
What is Dogwood Therapeutics Inc(DWTX)'s stock price today?
The current price of DWTX is $2.87. The 52 week high of DWTX is $23.50 and 52 week low is $1.62.
When is next earnings date of Dogwood Therapeutics Inc(DWTX)?
The next earnings date of Dogwood Therapeutics Inc(DWTX) is 2025-03-14 Est..
Does Dogwood Therapeutics Inc(DWTX) pay dividends? If so, how much?
Dogwood Therapeutics Inc(DWTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers